Onco3R Therapeutics

Onco3R Therapeutics is a Belgian clinical-stage biotech developing precision medicines for oncology and immunology with a portfolio of five disclosed programs. The company leverages a seasoned team with over 150 years of combined R&D experience and a dual-modality approach, utilizing both small molecules and antibodies to target clinically validated pathways. Its strategy focuses on designing best-in-class therapies by learning from the liabilities of first-generation drugs to improve safety and efficacy.

Integrated drug discovery expertise in both small molecules and antibodies (biologics), employing a modality-agnostic strategy to select the best therapeutic approach for clinically validated targets.

Onco3R operates in highly competitive fields. In oncology, it faces numerous companies developing FGFR inhibitors (e.g., Janssen, Taiho) and targeting SMARCA2/4 deficiencies (e.g., Foghorn Therapeutics). The P53 space is notoriously challenging but also crowded with experimental approaches. In immunology, SIK inhibition is an emerging area with several biotechs active. Its differentiation relies on superior drug design informed by first-generation liabilities.